FY2026 · ended Oct 31, 2025 · Revenue $5.20M, +12.5% YoY · Filed Oct 13, 2026
Zeo Scientifix, Inc (ZEOX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2026, which ended Oct 31, 2025, it reported revenue of $5.2 million and a net loss of $5.5 million. Free cash flow was -$741,000. As of Jun 30, 2026 it held $2.3 million in cash and investments and $337,000 in total debt.
Revenue
$5.20M
+12.5% vs prior year
Net income
$-5.52M
-17.3% vs prior year
Operating cash flow
$-718,000
+50.5% vs prior year
Free cash flow
$-741,000
+66.7% vs prior year
EPS
$-0.86
-16.2% vs prior year
Dividend per share
None
Shares outstanding
7.84M
+2.9% vs prior year
Net cash
$1.93M
FY 2026
Operating margin
-103.6%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ZEOX (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Davie, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1557376
- Former names
- Organicell Regenerative Medicine, Inc. (until Jan 29, 2024); Biotech Products Services & Research, Inc. (until Jun 15, 2018); BESPOKE TRICYCLES INC (until Sep 14, 2015)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Oct 31, 2025 |
FY 2024 Oct 31, 2024 |
FY 2023 Oct 31, 2023 |
FY 2022 Oct 31, 2022 |
FY 2021 Oct 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.2M | $4.6M | $4.6M | $6.5M | $5.6M |
| Operating income | -$5.4M | -$5.3M | -$6.8M | -$8.8M | -$12.7M |
| Net income | -$5.5M | -$4.7M | -$7.0M | -$8.9M | -$12.8M |
| Diluted EPS | -$0.86 | -$0.74 | -$0.99 | — | — |
| Operating cash flow | -$718,000 | -$1.4M | -$2.2M | -$3.2M | -$2.7M |
| Free cash flow | -$741,000 | — | -$2.2M | -$4.0M | -$3.1M |
| Total assets | $1.5M | $1.6M | $2.8M | $6.2M | $1.9M |
| Total liabilities | $3.0M | $3.3M | $4.0M | $4.3M | $4.6M |
| Stockholders' equity | -$1.4M | -$1.7M | -$1.2M | $1.9M | -$2.7M |
| Cash and investments | $221,000 | $657,000 | $1.8M | $3.8M | $108,570 |
| Total debt | $353,000 | $693,000 | $693,000 | $446,495 | $678,683 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 30, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 26, 2026 | Oct 26, 2026 |
| 10-KT | Transition report | Oct 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 15, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
All 518 Zeo Scientifix, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.